RELX:NYSERELX PLC PLC Analysis
Data as of 2026-04-28 - not real-time
$36.39
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
RELX trades at $36.39, comfortably above its 20‑day SMA ($34.85) and 50‑day SMA ($33.92) but still below the 200‑day SMA ($41.50), indicating a short‑term bounce within a longer‑term downtrend. Technical momentum is bullish with the MACD line ($0.80) above its signal ($0.61) and a histogram of $0.19, while the RSI of 62 suggests the stock is approaching overbought territory. Fundamentally, the company posts a robust operating margin of 31% and a profit margin of 21%, with a PE of 24 versus an industry average of 31, signaling relative value, yet its price‑to‑book ratio of 83 and debt‑to‑equity of 304% highlight a capital‑intensive balance sheet. The dividend yield of 2.53% and a payout ratio of 57% are supported by strong free cash flow ($2.16 B) and operating cash flow ($2.84 B), suggesting sustainability. Analysts have upgraded Citi’s outlook to Buy and set a median price target of $52.45, implying a 44% upside, while the DCF fair value of $13.28 appears overly conservative. Market sentiment is extremely bullish (Fear‑Greed Index 89), but the 30‑day volatility of 24% and a historic max drawdown of –50% underscore downside risk. The stock’s low beta (~0.23) reduces systematic risk, and volume remains stable, supporting liquidity. Overall, the blend of strong cash generation, attractive valuation multiples relative to peers, and a supportive dividend makes RELX a compelling candidate for medium‑term investors, though the high leverage and near‑term technical overbought signals advise caution.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish MACD with line above signal
- RSI near overbought at 62
- Support level at $32.13 and stable volume
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Target price $52.45 implies 44% upside
- PE 24 vs industry 31 indicates relative discount
- Strong margins and sustainable 2.53% dividend
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Consistent free cash flow supporting dividend
- High ROE (70%) despite leverage
- Diversified global exposure reducing geographic risk
Key Metrics & Analysis
Financial Health
Revenue Growth1.20%
Profit Margin21.53%
P/E Ratio24.1
ROE70.51%
ROA12.49%
Debt/Equity304.06
P/B Ratio83.0
Op. Cash Flow$2.8B
Free Cash Flow$2.2B
Industry P/E31.1
Technical Analysis
TrendNeutral
RSI62.6
Support$32.13
Resistance$37.78
MA 20$34.85
MA 50$33.92
MA 200$41.50
MACDBullish
VolumeStable
Fear & Greed Index89.25
Valuation
Fair Value$13.28
Target Price$52.45
Upside/Downside44.13%
GradeUndervalued
TypeValue
Dividend Yield2.53%
Risk Assessment
Beta0.42
Volatility24.06%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.